Monoclonal antibodies in multiple sclerosis Review article
Article Sidebar
Published:
Dec 31, 2012
Keywords:
multiple sclerosis, monoclonal antibodies, natalizumab, rituximab, daclizumab, alemtuzumab, ocrelizumab, ofatumumab
Main Article Content
Abstract
This paper provides an overview of issues related to multiple sclerosis therapy with monoclonal antibodies. The essential clinical trials using monoclonal antibodies in multiple sclerosis are discussed. Special attention is paid to the effectiveness and safety of the therapy.
Article Details
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Gensicke H., Leppert D., Yaldizli O. et al.: Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. CNS Drugs 2012; 26: 11-37.
2. Fontoura P.: Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges. MAbs. 2010 Nov-Dec; 2(6): 670-81.
3. Polman C.H., O’Connor P.W., Havrdova E. et al.: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006; 354(9): 899-910.
4. Tavazzi E., Ferrante P., Khalili K.: Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin. Microbiol. Infect. 2011 Dec; 17(12): 1776-80.
5. Coles A.J., Fox E., Vladic A. et al.: Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011; 10(4): 338-48.
6. CAMMS223 Trial Investigators; Coles A.J., Compston D.A., Selmaj K. et al.: Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 2008; 359: 1786-801.
7. Barun B., Bar-Or A.: Treatment of multiple sclerosis with anti-CD20 antibodies. Clin. Immunol. 2012 Jan; 142(1): 31-7.
8. Naismith R.T., Piccio L., Lyons J.A. et al.: Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010 Jun 8; 74(23): 1860-7.
9. Hawker K., O’Connor P., Freedman M.S. et al.: Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 2009 Oct; 66(4): 460-71.
10. Cross A.H., Klein R.S., Piccio L.: Rituximab combination therapy in relapsing multiple sclerosis. Ther. Adv. Neurol. Disord. 2012 Nov; 5(6): 311-9.
11. Kappos L., Calabresi P.A., O’Connor P. et al.: Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomized, placebo-controlled, multiplecentre trial. Lancet 2011; 387: 1779-87.
12. Castillo J., Milani C., Mendez-Allwood D.: Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin. Investig. Drugs 2009 Apr; 18(4): 491-500.
13. Rose J.W., Burns J.B., Bjorklund J. et al.: Daclizumab phase II trial in relapsing and remitting multiple sclerosis. Neurology 2007; 69: 785-9.
14. Wynn D., Kaufman M., Montalban X. et al.: Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomized, double-blind, placebo- controlled, add-on trial with interferon beta. Lancet Neurol. 2010 Apr; 9(4): 381-90.
15. Fernandez O., Alvarez-Cermeno J.C., Arroyo-Gonzalez R.; Post-ECTRIMS group: Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Rev. Neurol. 2012 Jun 16; 54(12): 734-49.
2. Fontoura P.: Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges. MAbs. 2010 Nov-Dec; 2(6): 670-81.
3. Polman C.H., O’Connor P.W., Havrdova E. et al.: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006; 354(9): 899-910.
4. Tavazzi E., Ferrante P., Khalili K.: Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin. Microbiol. Infect. 2011 Dec; 17(12): 1776-80.
5. Coles A.J., Fox E., Vladic A. et al.: Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011; 10(4): 338-48.
6. CAMMS223 Trial Investigators; Coles A.J., Compston D.A., Selmaj K. et al.: Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 2008; 359: 1786-801.
7. Barun B., Bar-Or A.: Treatment of multiple sclerosis with anti-CD20 antibodies. Clin. Immunol. 2012 Jan; 142(1): 31-7.
8. Naismith R.T., Piccio L., Lyons J.A. et al.: Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010 Jun 8; 74(23): 1860-7.
9. Hawker K., O’Connor P., Freedman M.S. et al.: Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 2009 Oct; 66(4): 460-71.
10. Cross A.H., Klein R.S., Piccio L.: Rituximab combination therapy in relapsing multiple sclerosis. Ther. Adv. Neurol. Disord. 2012 Nov; 5(6): 311-9.
11. Kappos L., Calabresi P.A., O’Connor P. et al.: Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomized, placebo-controlled, multiplecentre trial. Lancet 2011; 387: 1779-87.
12. Castillo J., Milani C., Mendez-Allwood D.: Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin. Investig. Drugs 2009 Apr; 18(4): 491-500.
13. Rose J.W., Burns J.B., Bjorklund J. et al.: Daclizumab phase II trial in relapsing and remitting multiple sclerosis. Neurology 2007; 69: 785-9.
14. Wynn D., Kaufman M., Montalban X. et al.: Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomized, double-blind, placebo- controlled, add-on trial with interferon beta. Lancet Neurol. 2010 Apr; 9(4): 381-90.
15. Fernandez O., Alvarez-Cermeno J.C., Arroyo-Gonzalez R.; Post-ECTRIMS group: Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Rev. Neurol. 2012 Jun 16; 54(12): 734-49.